Fifth Third Bancorp Reduces Stake in Jazz Pharmaceuticals PLC $JAZZ

Fifth Third Bancorp trimmed its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 26.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,671 shares of the specialty pharmaceutical company’s stock after selling 946 shares during the quarter. Fifth Third Bancorp’s holdings in Jazz Pharmaceuticals were worth $283,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. CX Institutional purchased a new position in Jazz Pharmaceuticals in the first quarter valued at about $4,316,000. Envestnet Portfolio Solutions Inc. boosted its stake in Jazz Pharmaceuticals by 38.9% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 4,369 shares of the specialty pharmaceutical company’s stock valued at $542,000 after acquiring an additional 1,223 shares during the last quarter. Inspire Investing LLC purchased a new position in Jazz Pharmaceuticals in the first quarter valued at about $689,000. Baird Financial Group Inc. purchased a new position in Jazz Pharmaceuticals in the first quarter valued at about $539,000. Finally, GAMMA Investing LLC boosted its stake in Jazz Pharmaceuticals by 63.7% in the first quarter. GAMMA Investing LLC now owns 1,015 shares of the specialty pharmaceutical company’s stock valued at $126,000 after acquiring an additional 395 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $131.80 on Wednesday. The company’s fifty day moving average price is $122.55 and its 200-day moving average price is $115.72. The firm has a market capitalization of $7.99 billion, a price-to-earnings ratio of -19.58, a PEG ratio of 8.00 and a beta of 0.24. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $148.06. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing analysts’ consensus estimates of ($5.61) by ($2.64). The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.05 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.Jazz Pharmaceuticals’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the previous year, the company earned $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, equities research analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total transaction of $771,720.00. Following the transaction, the director owned 429,973 shares of the company’s stock, valued at approximately $55,303,127.26. This trade represents a 1.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.30% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Truist Financial upped their price target on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a “buy” rating in a research note on Thursday, August 28th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They set a “buy” rating and a $152.00 price target on the stock. Zacks Research upgraded shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. Royal Bank Of Canada upped their price target on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an “outperform” rating in a research note on Thursday, August 28th. Finally, Morgan Stanley upped their price target on shares of Jazz Pharmaceuticals from $163.00 to $167.00 and gave the company an “overweight” rating in a research note on Wednesday, September 24th. Fourteen research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $178.93.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.